




































coagulation	 system	 in	 patients	 at	 high	 and	 very	 high	 cardiovascular	 risk	
according	to	the	SCORE	charts	in	the	presence	of	heart	rate	turbulence.	
	 Materials	 and	methods.	 	 603	patients	were	 examined	 to	determine	 the	
role	of	heart	rate	variability	in	the	cardiovascular	continuum;	319	patients	were	
examined	 to	 study	 the	 role	 of	 heart	 rate	 turbulence	 in	 the	 formation	 and	
progression	 of	 sudden	 death	 in	 the	 cardiovascular	 continuum	 based	 on	 the	
Holter	 monitoring.	 All	 patients	 were	 divided	 into	 4	 groups:	 Group	 1	 included	
patients	with	coronary	heart	disease	without	concomitant	 risk	 factors	such	as	
smoking,	obesity,	metabolic	 syndrome;	Group	2	 consisted	of	patients	 smoking	
tobacco	 for	 more	 than	 2	 years;	 Group	 3	 included	 patients	 with	 metabolic	
syndrome	 without	 existing	 coronary	 heart	 disease	 or	 arterial	 hypertension;	
Group	 4	 consisted	 of	 patients	 with	 metabolic	 syndrome	 and	 arterial	
hypertension.	 The	 control	 group	 included	 149	 people.	 In	 patients	 with	
ventricular	 extrasystoles	 of	 different	 degrees	 according	 to	 V.	 Lown’s	 and	 M.	
Wolf’s	scale	 the	 phenomenon	 of	 heart	 rate	 turbulence	 was	 observed	 and	 the	
parameters	of	the	blood	coagulation	system	were	determined.	
	 Results.	 There	 was	 no	 significant	 difference	 between	 indices	 of	
coagulation	among	studied	groups	and	the	control	group.	In	patients	with	post-
infarction	 cardiosclerosis	 hematocrit	 was	 lower	 due	 to	 regular	 intake	 of	
antiplatelet	drugs	to	prevent	the	progression	of	coronary	heart	disease.	It	can	be	
stated	 that	 the	phenomenon	of	heart	 rate	 turbulence	 itself	does	not	affect	 the	
change	 in	 the	 coagulation	 system	 of	 the	human	 body.	When	determining	 the	























cardiac	 death.	 The	 latter	 is	 performed	 in	 patients	 who	 were	 saved	 from	 sudden	 cardiac	 death.	
Primary	 prevention	 is	 a	 series	 of	 therapeutic	 measures	 in	 patients	 at	 increased	 risk	 of	 sudden	
cardiac	death	[5].	Considering	all	the	mentioned	above,	it	is	clear	that	the	main	way	to	reduce	losses	
from	sudden	cardiac	death	 is	 the	primary	prevention.	The	existing	selection	criteria	 for	primary	
prevention	of	sudden	cardiac	death	are	not	sufficiently	effective	 [3].	 In	 this	regard,	an	 important	
task	is	to	improve	the	existing	criteria	for	primary	prevention	of	sudden	cardiac	death	as	well	as	to	
search	 for	new	ones;	 to	separate	patients	at	 increased	 risk	of	sudden	cardiac	death.	 It	should	be	
noted,	 that	 most	 of	 them	 are	 those	 with	 structural	 heart	 diseases;	 80%	 of	 patients	 suffer	 from	
coronary	 heart	 disease	 and	 hypertension,	 15%	 of	 patients	 are	 diagnosed	 with	 non-ischemic	
cardiomyopathy	and	only	5%	of	patients	do	not	have	any	structural	heart	disease	[6,	7].	Thrombosis	
is	 one	 of	 the	 most	 severe	 complications	 of	 heart	 disease	 and	 its	 consequences	 are	 difficult	 to	
predict:	it	can	result	in	the	embolization	of	cerebral	vessels	with	further	development	of	ischemic	
stroke	 as	well	 as	 in	 the	 embolization	 of	 the	 coronary	 artery	with	 further	 development	 of	 acute	
coronary	syndrome,	or	embolization	of	the	pulmonary	arterial	branches.	Each	of	these	effects	can	




and	 treatment	 of	 coronary	 heart	 disease	 is	 described	 in	 many	 research	 works.	 If	 a	 patient	 is	
diagnosed	with	coronary	heart	disease	the	mandatory	component	in	his/her	treatment	should	be	
antiplatelet	 drug	 aspirin,	 and	 in	 case	 of	 intolerance,	 it	 may	 be	 clopidogrel.	 In	 case	 of	 atrial	
fibrillation	 or	 atrial	 flutter	 the	 usage	 of	 warfarin	 is	 recommended.	 In	 the	 last	 2-3	 years	 new	



































however,	 the	number	 of	 extrasystoles	did	not	 exceed	normal	 values.	One	 of	 the	 criteria	 for	 the	
development	of	sudden	cardiac	death	is	increased	blood	clotting	and	thrombosis.	The	presence	of	
ectopic	 heartbeat	 itself	 increases	 the	 risk	 of	 thrombosis.	 To	 identify	 the	 risk	 of	 thrombosis	 in	
patients	 with	 the	 phenomenon	 of	 heart	 rate	 turbulence	 the	 analysis	 of	 coagulation	 profile	





























































time,	 fibrinogen	 level	 and	 thrombotest	 values.	 	 In	 patients	 with	 post-infarction	 cardiosclerosis	
hematocrit	was	significantly	 lower	 (p<0.01)	due	 to	 regular	 intake	of	antiplatelet	drugs	 to	prevent	
the	 progression	 and	 complications	 of	 coronary	 heart	 disease.	 In	 people	 of	 Group	 1	 trombotest	
values	were	 lower	 than	 in	 the	control	group	-	4.16	+	1.15	vs.	0.37	+	5.0.37.	The	 level	of	 fibrinogen	
was	also	lower	in	patients	of	Group	1	-	2.47	+	0.15	vs.	2.82	+	0.23.	There	was	no	significant	difference	
in	 the	 parameters	 of	 coagulation	 profile	 between	 patients	 of	Group	 2	 and	 the	 control	 group.	 In	
patients	at	very	high	cardiovascular	risk	activated	recalcification	time	was	 longer	than	that	 in	all	
studied	groups.	In	patients	of	Group	3	there	was	no	significant	difference	between	the	parameters	




	 There	 was	 no	 significant	 difference	 in	 the	 parameters	 of	 coagulation	 profile	 between	
studied	 groups	 and	 the	 control	 group;	 only	 in	 patients	 with	 post-infarction	 cardiosclerosis	
hematocrit	 was	 lower	 due	 to	 regular	 intake	 of	 antiplatelet	 drugs	 to	 prevent	 the	 progression	 of	
coronary	heart	disease.	It	can	be	stated	that	the	phenomenon	of	heart	rate	turbulence	 itself	does	
not	 affect	 the	 change	 in	 the	 coagulation	 system	 of	 the	 human	 body.	 When	 determining	 the	
advisability	of	administering	anticoagulants	to	patients	with	heart	rate	turbulence,	we	should	be	
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